Study shows combination of lenalidomide, idelalisib and rituximab were unacceptably toxic for replased indolent lymphoma (first page only)
Home / Resource Library / Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma